Solara Active Pharma Sciences Limited

BSE: 541540 NSE: SOLARA
Solara Active Pharma Sciences Limited - pharma in Thane, Maharashtra, India. FY 2026 financials & compliance.
CIN L24230MH2017PLC291636 Incorporated 23 February 2017 ROC Mumbai HQ Thane, Maharashtra, India
Active Listed - NSE: SOLARA · BSE: 541540 Public Limited Company pharma
Data last updated
Market Cap
₹3,530 Cr
SOLARA · NSE
Share Price
₹739.15
+1.62% today
Revenue
₹1,369 Cr
FY 2025-26 · +10.3% YoY
EBITDA
₹181 Cr
Margin 13.2%
Net Profit
−₹1.52 Cr
FY 2025-26
P/E (TTM)
-
P/B 2.8x
ROE
0.0%
ROCE 0.0%
Debt / Equity
0.63
Interest cover 116.7x

About Solara Active Pharma Sciences Limited

Data last updated: 25 September 2026

Solara Active Pharma Sciences Limited is a public limited company based in Thane, Maharashtra, India. It specialises in api manufacturers, a part of the broader pharmaceuticals sector. Incorporated on 23 February 2017, the company has been in operation for over 9 years.

Registered with ROC Mumbai under CIN L24230MH2017PLC291636. Listed on BSE: 541540 and NSE: SOLARA.

Capital: an authorised share capital of ₹120 Cr and a paid-up capital of ₹47.98 Cr. Formerly known as Ssl Pharma Sciences Limited. It is led by directors including Ramakrishnan Rajagopal and Kausalya Santhanam.

Last AGM: 25 September 2025. Financial statements filed for year ended 31 March 2025. Office: Sector 30, Thane, Maharashtra.

As per the latest consolidated financials for FY 2025-26, the company reported a revenue of ₹1,368.98 Cr, a growth of 6.64% compared to the previous year. The net worth stands at ₹1,252.88 Cr (up 14.5% YoY). Total assets are valued at ₹1,995.58 Cr (up 2.22% YoY).

The company has a workforce of approximately 1,656 employees as per the latest available data. Its group structure includes 2 subsidiaries.

The company is associated with 1 brand - Solara Active Pharma Sciences. As per MCA filings, the company has open charges of ₹507.5 Cr and satisfied charges of ₹2,480.69 Cr on record.

The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website solara.co.in.

Company Details of Solara Active Pharma Sciences Limited
CIN L24230MH2017PLC291636
Registration Number 291636
Incorporation Date 23 February 2017
ROC Mumbai
Listing Status Listed (BSE: 541540, NSE: SOLARA)
Company Status Active
Date of Last AGM 25 September 2025
Date of Balance Sheet 31 March 2025
Compliance Status Active Compliant
Key People
Sandeep Shashikantha Rao Managing Director Sanjeevi Mohanraj Whole-Time Director Ramakrishnan Rajagopal Director
Contact Details
  • Email
    Locked
  • Telephone
    Locked
  • Website
    solara.co.in
  • Social Media
    Locked
  • Registered Address
    Cyber One Unit No. 902 Sector 30A, Plot No. 4 & 6 Vashi Navi Mumbai, Thane, Maharashtra, India – 400703
  • Industry
    Pharma, API Manufacturers
Company report
Solara Active Pharma Sciences Limited - full intelligence report
  • Historical Financials and ratios
  • Shareholding pattern and group structure
  • Charges with holder and property details
  • Litigation, compliance and MCA filings
  • PDF report delivered after checkout
₹799 ₹999 20% off
Secure checkout · GST invoice included

Unlock the full Solara Active Pharma Sciences Limited report

Financials, compliance, directors, charges, ownership and filings for Solara Active Pharma Sciences Limited in one report.

10-year financials Directors & ownership Charges & compliance

CIN History of Solara Active Pharma Sciences Limited

Solara Active Pharma Sciences Limited has one previous CIN (Corporate Identification Number): U24230MH2017PLC291636. The current CIN is L24230MH2017PLC291636, which is the unique identifier assigned by the Registrar of Companies.

CIN Status
L24230MH2017PLC291636 Current
U24230MH2017PLC291636 Previous

Associated Brands with Solara Active Pharma Sciences Limited

Solara Active Pharma Sciences Limited operates one associated brand: Solara Active Pharma Sciences. These brands represent Solara Active Pharma Sciences Limited's diversified market presence and brand portfolio.

Brand Description Website
Solara Active Pharma Sciences
APIs and intermediates are manufactured for therapeutic categories. solara.co.in

Business Activity of Solara Active Pharma Sciences Limited

Solara Active Pharma Sciences Limited is engaged in the principal business activity of manufacturing, with detailed activities including chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.

Main Activity Group Code Description of Main Activity Business Activity Code Description of Business Activity Turnover Percentage
C Manufacturing C6 Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products Locked
Premium access

Business activity turnover details for Solara Active Pharma Sciences Limited

Turnover contribution percentages and historical activity changes require an active report plan.

  • Turnover contribution
  • Historical classifications
  • Filing-level activity changes

Verified entity values are shown only after access is granted.

Auditor Details of Solara Active Pharma Sciences Limited

Solara Active Pharma Sciences Limited is audited by Deloitte Haskins & Sells LLP for the financial year 2023. The auditor plays a crucial role in ensuring financial transparency and compliance with accounting standards.

Name Status Appointment Date Cessation Date
Deloitte Haskins & Sells LLP Locked Locked Locked
Premium access

Complete auditor history for Solara Active Pharma Sciences Limited

Appointment status, appointment dates, cessation dates, and historical auditor changes require an active report plan.

  • Appointment status
  • Appointment dates
  • Cessation dates
  • Auditor changes

Verified entity values are shown only after access is granted.

Board of Directors of Solara Active Pharma Sciences Limited

Solara Active Pharma Sciences Limited is currently managed by 8 directors, with 19 former directors having served the organization. The current Directors play a crucial role in shaping the company's strategic direction and governance.

Current Directors
Name Designation Appointment Date Tenure Status
Ramakrishnan Rajagopal
Also directs: Solara Active Pharma Sciences Limited, Synthix Global Pharma Solutions Limited, Multivision Business Solutions Private Limited and 1 more
Director 11 Apr 2018 8 Years 5 Months Current
Kausalya Santhanam
Also directs: Strides Pharma Science Limited, Solara Active Pharma Sciences Limited, Synthix Global Pharma Solutions Limited and 2 more
Director 11 Apr 2018 8 Years 5 Months Current
Arun Kumar Pillai
Also directs: Chayadeep Ventures Llp, Agnus Capital Llp, Karuna Group Llp and 3 more
Director 04 Aug 2021 5 Years 1 Months Current
Sandeep Shashikantha Rao
Also directs: Solara Active Pharma Sciences Limited
Managing Director 21 Feb 2025 1 Years 7 Months Current
Manish Gupta
Also directs: Solara Active Pharma Sciences Limited, Synthix Global Pharma Solutions Limited, Jagson Pal Pharmaceuticals Limited. and 1 more
Director 22 Jul 2024 2 Years 2 Months Current
Rajendra Kumar Srivastava
Also directs: Solara Active Pharma Sciences Limited, Latticed Advisors Llp, Happiest Minds Technologies Limited and 1 more
Director 14 Nov 2023 2 Years 10 Months Current
Showing 6 of 8 current directors. View all directors

Financials of Solara Active Pharma Sciences Limited FY 2025-26 filings available

Solara Active Pharma Sciences Limited reported revenue of ₹1,368.98 Cr (up 6.64% YoY) for FY 2025-26.

Financial Highlights

FY 2025-26 · Consolidated
Revenue
₹1,369 Cr
+6.6% YoY
EBITDA
₹181 Cr
-12.3% YoY
Profit After Tax
−₹1.52 Cr
-381.5% YoY
Net Worth
₹1,253 Cr
+14.5% YoY
Total Assets
₹1,996 Cr
+2.2% YoY
Total Debt
₹687 Cr
-13.8% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue1,3691,2841,2891,4441,2681,6171,322
Revenue growth+10.3%-31.6%+20.2%+9.9%-3.2%+15.9%-9.5%
EBITDA181206(285)13476.48386259
EBITDA margin+13.2%+16.1%-22.1%+9.3%+6.0%+23.9%+19.6%
Profit before tax(7.41)0.54(488)(44.82)(91.10)222115
Net profit(1.52)0.54(408)(21.73)(53.90)220115
Net profit margin-0.1%+0.0%-31.7%-1.5%-4.3%+13.6%+8.7%
EPS (₹)(1.66)0.13(157.61)(6.16)(16.15)61.6242.69
Balance sheet
Total assets1,9961,9522,0022,5652,6252,2791,888
Net worth1,2531,0949341,5001,5251,5891,086
Total debt6877961,0121,0131,037621722
Cash & bank50.344.118.608.8947.2519956.78
Net working capital518449452853919723419
Cash flow
Cash from operations153213109156(242)155242
Cash from investing(98.83)(36.83)(3.51)(81.14)(243)(106)(359)
Cash from financing(53.55)(180)(106)(113)33492.4996.98
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue382387349314319273300347
Revenue growth (YoY)+19.6%+41.9%+16.2%-9.6%-12.2%-8.8%+41.7%-18.4%
Other income2.695.550.000.490.985.951.490.32
EBITDA61.9757.6630.5934.7357.0245.3757.6861.31
EBITDA margin+16.2%+14.9%+8.8%+11.1%+17.9%+16.6%+19.2%+17.7%
Depreciation26.7126.0425.5724.4923.5824.3024.5425.34
Interest21.6427.5722.4520.8323.9029.1226.5428.28
Profit before tax16.319.60(17.43)(10.10)10.52(2.10)8.098.01
Tax0.000.000.000.000.000.000.000.00
Net profit16.319.60(17.43)(10.10)10.52(2.10)8.098.01
EPS (₹)3.522.20(3.98)(2.36)2.46(0.93)2.032.54
MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue1,3691,2841,2891,4441,2681,6171,322
Revenue growth+10.0%-31.4%+20.1%+9.9%-3.3%+15.6%-9.2%
EBITDA181204(285)13476.86385257
EBITDA margin+13.2%+15.9%-22.1%+9.3%+6.1%+23.8%+19.4%
Profit before tax(7.24)(1.08)(488)(44.78)(91.66)221112
Net profit(1.35)(1.08)(408)(21.76)(54.30)219113
Net profit margin-0.1%-0.1%-31.7%-1.5%-4.3%+13.6%+8.5%
EPS (₹)(1.63)(0.27)(157.46)(6.17)(16.27)61.5041.90
Balance sheet
Total assets1,9461,9512,0032,5652,6252,2791,889
Net worth1,2551,0969371,5031,5271,5931,091
Total debt6377961,0121,0131,037621722
Cash & bank4.163.978.488.7147.1419856.58
Net working capital478455447861927727424
Cash flow
Cash from operations153213111156(242)154242
Cash from investing(50.14)(36.83)(4.66)(81.13)(243)(105)(359)
Cash from financing(103)(180)(107)(113)33492.5097.01
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue382387349314319273300347
Revenue growth (YoY)+19.6%+41.9%+16.2%-9.6%-12.2%-8.8%+41.7%-18.4%
Other income1.925.280.000.490.985.951.490.32
Total expenses320330318279262230243286
EBITDA62.0157.5530.6034.7557.0342.5957.6961.32
EBITDA margin+16.3%+14.9%+8.8%+11.1%+17.9%+15.6%+19.2%+17.7%
Depreciation26.7126.0425.5724.4923.5824.3024.5425.34
Interest20.2327.0622.4520.8323.9029.1226.5428.28
Profit before tax16.999.73(17.42)(10.08)10.53(4.88)8.108.02
Tax0.000.000.000.000.000.000.000.00

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 25 Sep 2026
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue382387349314319273300347
Revenue growth (YoY)+19.6%+41.9%+16.2%-9.6%-12.2%-8.8%+41.7%-18.4%
Other income2.695.550.000.490.985.951.490.32
EBITDA61.9757.6630.5934.7357.0245.3757.6861.31
EBITDA margin+16.2%+14.9%+8.8%+11.1%+17.9%+16.6%+19.2%+17.7%
Depreciation26.7126.0425.5724.4923.5824.3024.5425.34
Interest21.6427.5722.4520.8323.9029.1226.5428.28
Profit before tax16.319.60(17.43)(10.10)10.52(2.10)8.098.01
Tax0.000.000.000.000.000.000.000.00
Net profit16.319.60(17.43)(10.10)10.52(2.10)8.098.01
EPS (₹)3.522.20(3.98)(2.36)2.46(0.93)2.032.54
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue1,3691,2841,2891,4441,2681,6171,322
Revenue growth+10.3%-31.6%+20.2%+9.9%-3.2%+15.9%-9.5%
Other income6.168.325.3722.5520.0228.7727.52
Total expenses1,1881,0771,5741,3101,1921,2311,062
Employee cost224215247229236229204
EBITDA181206(285)13476.48386259
EBITDA margin+13.2%+16.1%-22.1%+9.3%+6.0%+23.9%+19.6%
Depreciation99.6899.2510311111210994.16
Interest94.7511510590.0675.2884.4877.89
Profit before tax(7.41)0.54(488)(44.82)(91.10)222115
Tax0.000.0078.54(22.57)(32.81)0.150.39
Net profit(1.52)0.54(408)(21.73)(53.90)220115
Net profit margin-0.1%+0.0%-31.7%-1.5%-4.3%+13.6%+8.7%
EPS (₹)(1.66)0.13(157.61)(6.16)(16.15)61.6242.69
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital44.5140.2536.0036.0036.0035.9326.85
Reserves & surplus1,2081,0548981,4641,4891,553963
Shareholders' funds (net worth)1,2531,0949341,5001,5251,5891,086
Minority interest2.672.672.672.242.314.244.29
Secured loans6657399081,0011,025607707
Unsecured loans22.0257.5210311.7012.8013.8215.17
Total debt6877961,0121,0131,037621722
Total liabilities1,9961,9522,0022,5652,6252,2791,888
Assets
Gross block2,0381,8991,8791,8951,7791,7021,611
Net block1,2381,1931,2681,3641,3561,3821,397
Capital work in progress20528025623823987.9840.47
Investments4.621.701.701.700.420.420.32
Inventories318318360558576295280
Sundry debtors439327349537490484227
Cash & bank balances50.344.118.608.8947.2519956.78
Loans & advances48.1780.1583.9383.5712780.25109
Total current assets8557298011,1881,2391,058672
Total current liabilities337280349335320335253
Net working capital518449452853919723419
Total assets1,9961,9522,0022,5652,6252,2791,888
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash3.958.448.7346.3819856.0475.72
Net cash from operating activities153213109156(242)155242
Net cash from investing activities(98.83)(36.83)(3.51)(81.14)(243)(106)(359)
Net cash from financing activities(53.55)(180)(106)(113)33492.4996.98
Net change in cash0.53(4.49)(0.29)(37.65)(151)142(19.68)
Closing cash50.344.118.608.8947.2519956.78
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+6.6%-0.4%-10.7%+13.8%-21.6%+22.3%-4.7%
EBITDA growth-12.3%+9998.0%-+75.1%-80.2%+48.7%+21.7%
PBT growth-+9998.0%-989.7%+50.8%-+92.8%+91.6%
Net income growth-+9998.0%-1778.1%+59.7%-+91.3%+94.1%
Revenue CAGR (3Y)-1.8%+0.4%-7.3%+3.0%-2.9%+45.9%-
EBITDA CAGR (3Y)+10.6%+39.2%--19.8%-28.9%+89.3%-
Profitability & leverage
Net income margin-0.5%+0.0%-44.0%-1.5%-4.6%+13.7%+8.7%
Return on capital employed0.0%+5.4%0.0%+1.7%-0.7%+14.7%+11.1%
Return on net worth0.0%+0.1%0.0%-1.5%-3.7%+16.6%+11.2%
Debt / equity0.630.890.830.680.530.500.62
Long-term debt / equity0.110.120.150.180.150.150.23
Interest cover116.72107.27-27.04396.91-210.0430.4847.13
Efficiency & per share
Fixed asset turnover0.700.680.680.790.730.980.90
Inventory turnover4.313.792.812.552.915.635.35
Debtors turnover3.583.802.912.812.614.555.13
EPS (₹)(1.66)0.13(157.61)(6.16)(16.15)61.6242.69
Dividend per share (₹)0.000.000.003.000.007.002.00
Book value per share (₹)281.48271.86259.42416.73423.57442.12368.69
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue382387349314319273300347
Revenue growth (YoY)+19.6%+41.9%+16.2%-9.6%-12.2%-8.8%+41.7%-18.4%
Other income1.925.280.000.490.985.951.490.32
Total expenses320330318279262230243286
EBITDA62.0157.5530.6034.7557.0342.5957.6961.32
EBITDA margin+16.3%+14.9%+8.8%+11.1%+17.9%+15.6%+19.2%+17.7%
Depreciation26.7126.0425.5724.4923.5824.3024.5425.34
Interest20.2327.0622.4520.8323.9029.1226.5428.28
Profit before tax16.999.73(17.42)(10.08)10.53(4.88)8.108.02
Tax0.000.000.000.000.000.000.000.00
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue1,3691,2841,2891,4441,2681,6171,322
Revenue growth+10.0%-31.4%+20.1%+9.9%-3.3%+15.6%-9.2%
Other income5.899.145.3722.1418.7628.4127.51
Total expenses1,1881,0801,5741,3101,1911,2321,065
Employee cost224215247228234228202
EBITDA181204(285)13476.86385257
EBITDA margin+13.2%+15.9%-22.1%+9.3%+6.1%+23.8%+19.4%
Depreciation99.6899.2510311111210893.67
Interest94.2411510690.0675.2784.4777.88
Profit before tax(7.24)(1.08)(488)(44.78)(91.66)221112
Tax0.000.0078.54(22.57)(33.10)0.000.00
Net profit(1.35)(1.08)(408)(21.76)(54.30)219113
Net profit margin-0.1%-0.1%-31.7%-1.5%-4.3%+13.6%+8.5%
EPS (₹)(1.63)(0.27)(157.46)(6.17)(16.27)61.5041.90
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital44.5140.2536.0036.0036.0035.9326.85
Reserves & surplus1,2111,0569011,4671,4911,557968
Shareholders' funds (net worth)1,2551,0969371,5031,5271,5931,091
Secured loans6157399081,0011,025607707
Unsecured loans22.0257.5210311.7012.8013.8215.17
Total debt6377961,0121,0131,037621722
Total liabilities1,9461,9512,0032,5652,6252,2791,889
Assets
Gross block2,0311,8921,9331,8711,7641,6781,587
Net block1,2311,1871,2611,3421,3341,3591,374
Capital work in progress20528025623823987.7240.21
Investments1.631.7014.2516.0514.7718.1318.03
Inventories318318360558576295280
Sundry debtors439327351540490484230
Cash & bank balances4.163.978.488.7147.1419856.58
Loans & advances47.7980.1671.2584.4212880.83109
Total current assets8097297911,1911,2401,058675
Total current liabilities331274344330312331251
Net working capital478455447861927727424
Total assets1,9461,9512,0032,5652,6252,2791,889
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash3.818.328.5546.2719855.8475.62
Net cash from operating activities153213111156(242)154242
Net cash from investing activities(50.14)(36.83)(4.66)(81.13)(243)(105)(359)
Net cash from financing activities(103)(180)(107)(113)33492.5097.01
Net change in cash0.19(4.51)(0.23)(37.72)(151)142(19.78)
Closing cash4.163.978.488.7147.1419856.58
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+6.6%-0.4%-10.7%+13.8%-21.6%+22.3%-4.7%
EBITDA growth-11.3%+9998.0%-+74.4%-80.1%+50.2%+20.0%
PBT growth-570.4%+99.8%-990.5%+51.2%-+96.4%+85.4%
Net income growth-25.0%+99.7%-1775.1%+59.9%-+94.5%+93.2%
Revenue CAGR (3Y)-1.8%+0.4%-7.3%+3.0%-2.9%+45.9%-
EBITDA CAGR (3Y)+10.5%+38.4%--19.5%-28.9%+87.3%-
Profitability & leverage
Net income margin-0.5%-0.1%-44.0%-1.5%-4.6%+13.7%+8.5%
Return on capital employed0.0%0.0%0.0%+1.7%-0.7%+14.7%+11.0%
Return on net worth0.0%0.0%0.0%-1.5%-3.8%+16.5%+11.0%
Debt / equity0.610.890.830.680.530.500.61
Long-term debt / equity0.090.120.150.180.150.150.23
Interest cover116.19109.77-27.33389.20-214.1430.4947.82
Efficiency & per share
Fixed asset turnover0.700.670.680.790.740.990.91
Inventory turnover4.313.792.812.552.915.635.35
Debtors turnover3.583.792.892.812.614.535.08
EPS (₹)(1.63)(0.27)(157.46)(6.17)(16.27)61.5041.90
Dividend per share (₹)0.000.000.003.000.007.002.00
Book value per share (₹)282.06272.35260.39417.54424.18443.30370.50
Want more history and ratios?
You're viewing the latest exchange-filed financials for Solara Active Pharma Sciences Limited. The full report adds 10+ years of line-item history, 20+ ratios, peer benchmarks and a downloadable PDF.
10+ years of history 20+ ratios & benchmarks Downloadable PDF

Shareholding Pattern of Solara Active Pharma Sciences Limited

As per the shareholding pattern for the quarter ended Jun 2026, promoters hold 41.90%, foreign institutional investors hold 11.50%, domestic institutional investors hold 3.80%, retail and other public shareholders hold 42.80% of Solara Active Pharma Sciences Limited.

Promoters: 41.90%DII (Domestic Institutional): 3.80%FII (Foreign Institutional): 11.50%Retail & Others: 42.80%
Jun 2026
QUARTER
41.90% Promoters
3.80% DII (Domestic Institutional)
11.50% FII (Foreign Institutional)
42.80% Retail & Others
Promoter holding - history
Now 41.90% · Jun 2026High 42.00% · Sep 2025Low 41.90% · Jun 2026
40%40.8%41.5%42.3%43%Sep 2025Dec 2025Mar 2026Jun 2026Sep 2025: 42.00%Dec 2025: 42.00%Mar 2026: 42.00%Jun 2026: 41.90%42.00%41.90%
Shareholding trend - last 6 quarters
Jun 2026Mar 2026Dec 2025Sep 2025
Promoters41.90%42.00%42.00%42.00%
Public58.10%58.00%58.00%58.00%

Group Structure of Solara Active Pharma Sciences Limited

Solara Active Pharma Sciences Limited has 2 subsidiary companies. This group structure data is as of FY 2023. The corporate group structure reflects Solara Active Pharma Sciences Limited's business expansion strategy and organizational complexity.

2
Subsidiary companies
Key Subsidiaries
Company Name CIN Shares Held
Sequent Penems Private Limited U24233KA2010PTC053548 -
Chemsynth Laboratories Private Limited U24297TG2009PTC064991 -

Showing major subsidiaries. Total: 2.

Charges & Borrowings of Solara Active Pharma Sciences Limited

Open charges
₹507.5 Cr
Satisfied charges
₹2,480.69 Cr
Breakdown by lending institutions
Others₹367.50 Cr
Yes Bank Limited₹140.00 Cr
Latest charge details
DateLenderAmountStatus
30 Jan 2025 Others ₹75 Cr Open
28 Sep 2022 Yes Bank Limited ₹75 Cr Open
28 Sep 2022 Yes Bank Limited ₹65 Cr Open
22 Nov 2021 Others ₹150 Cr Open
30 May 2019 Others ₹142.5 Cr Open

Total charge records: 26 View all charges

Employees and EPFO Compliance at Solara Active Pharma Sciences Limited

Solara Active Pharma Sciences Limited has a workforce of 1,656 employees as of Mar 25, 2024.

Employee count
1,656
Active EPFO establishments
7
Employee growth
6.29%
Premium access

Employee and EPFO history for Solara Active Pharma Sciences Limited

Monthly headcount, contribution history, establishment records, and filing compliance require an active report plan.

  • Monthly headcount
  • PF contributions
  • ECR filing status
  • Establishment history

Verified entity values are shown only after access is granted.

GST Compliance of Solara Active Pharma Sciences Limited

Premium access

GST registrations and filing compliance for Solara Active Pharma Sciences Limited

State-wise registrations, return filing status, HSN and SAC details, and jurisdiction records require an active report plan.

  • GSTIN registrations
  • State-wise filing status
  • HSN and SAC details
  • Tax jurisdiction records

Verified entity values are shown only after access is granted.

Credit Ratings, Litigation & Regulatory Alerts for Solara Active Pharma Sciences Limited

Premium access

Credit ratings, litigation, and regulatory alerts for Solara Active Pharma Sciences Limited

Agency ratings, court records, regulatory events, and entity-specific compliance alerts require an active report plan.

  • Rating history
  • Court and tribunal cases
  • Regulatory alerts
  • Director-linked violations

Verified entity values are shown only after access is granted.

MSME Payment Delays by Solara Active Pharma Sciences Limited

Premium access

MSME payment history for Solara Active Pharma Sciences Limited

Amounts outstanding to micro and small suppliers, delay reasons, and MSME-1 filing history require an active report plan.

  • Outstanding amounts
  • Delay periods and reasons
  • MSME-1 filing history
  • Vendor payment signals

Verified entity values are shown only after access is granted.

Subsidiaries & Group Companies of Solara Active Pharma Sciences Limited

Premium access

Corporate group structure for Solara Active Pharma Sciences Limited

Parent, subsidiary, associate, joint venture, and ownership records require an active report plan.

  • Parent company
  • Subsidiaries and ownership
  • Associates and joint ventures
  • Entity investments

Verified entity values are shown only after access is granted.

MCA Filings & Documents of Solara Active Pharma Sciences Limited

Premium access

MCA filings and documents for Solara Active Pharma Sciences Limited

Official forms, annual returns, financial statements, charge filings, and document dates require an active report plan.

  • Incorporation documents
  • Annual returns and statements
  • Charge filings
  • Complete filing index

Verified entity values are shown only after access is granted.

Recent Activity on Solara Active Pharma Sciences Limited

Charges
11 May 2026
A charge registered on 21 Jan 2021 via Charge ID 100413686 with Others was fully satisfied on 11 May 2026.
Charges
05 Feb 2026
A charge with Others of Rs. 142.50 Cr registered on 30 May 2019 with Charge ID 100268311 was modified on 05 Feb 2026.
Charges
14 Jan 2026
A charge with Others of Rs. 75.00 Cr registered on 30 Jan 2025 with Charge ID 101045752 was modified on 14 Jan 2026.
Directors
01 Jan 2026
Sanjeevi Mohanraj was appointed as a Whole-Time Director on 01 Jan 2026 & has been associated with this company since 8 months 25 days.
Activity
25 Sep 2025
Solara Active Pharma Sciences Limited last Annual general meeting of members was held on 25 Sep 2025 as per latest MCA records.
Directors
02 Jun 2025
Pooja Jaya Kumar was appointed as a Company Secretary on 02 Jun 2025 & has been associated with this company since 1 year 3 months.

Recent News on Solara Active Pharma Sciences Limited

Stocks that will see action: January 24, 2025
24 Jan 2025 · Thehindubusinessline

Frequently Asked Questions about Solara Active Pharma Sciences Limited

Solara Active Pharma Sciences Limited is an active public limited company in the pharma sector based in Thane, Maharashtra, India. It was incorporated on 23 February 2017 (9+ years old) and is registered under CIN L24230MH2017PLC291636. Listed on BSE: 541540 and NSE: SOLARA. The company has 1,656 employees.

Solara Active Pharma Sciences Limited reported revenue of ₹1,368.98 Cr for FY 2025-26 (up 6.64% YoY) based on consolidated financials.

The current directors of Solara Active Pharma Sciences Limited are:

The primary industry of Solara Active Pharma Sciences Limited is pharma. The company specifically operates in api manufacturers. The company is currently active in this sector.

Yes. Solara Active Pharma Sciences Limited is listed on both BSE (code: 541540) and NSE (symbol: SOLARA).

Solara Active Pharma Sciences Limited can be reached at the registered office: Cyber One Unit No. 902 Sector 30A, Plot No. 4 & 6 Vashi Navi Mumbai, Thane, Maharashtra, India – 400703, or through the website solara.co.in.

7M+ Indian companies. One platform.

Financials, directors, compliance, charges and shareholding - compiled from official filings and updated regularly.

Subscription plans available